Antaros Medical is discussing how using imaging can add value in chronic kidney disease drug development at the CKD Summit

Later this week at the 5th Chronic Kidney Disease (CKD) Drug Development Summit, Jonas Svensson (Director MR Imaging at Antaros Medical) will present about advances in kidney imaging for drug development.

Chronic kidney disease, the gradual loss of kidney function, is a worldwide health problem. It is estimated that between 8-10% of the adult population has some form of kidney damage.

Established biomarkers for assessing kidney disease in drug development have their limitations. This can be with regards to poor reproducibility, insensitivity to early disease detection, feasibility and safety issues, and sampling bias. Quantitative Magnetic Resonance Imaging (MRI) offers the potential to assess renal structure, function, and pathophysiology with precision and good reproducibility.

To find out more, join us at the CKD Summit on Wednesday 8 March @ 11:30 to hear Jonas speak about using imaging in kidney drug development. The CKD Summit takes place from March 7-9 in Boston, MA. You can also read more about our work in kidneys in Our work or in our Publications.

Share on Linkedin Share on Twitter